Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma

Abstract

Oral panobinostat (Farydak®), a potent nonselective histone deacetylase inhibitor, is approved in several countries for use in combination with bortezomib and dexamethasone in patients with multiple myeloma (MM) [USA] or relapsed and/or refractory MM (EU) who have received at least two prior treatment regimens, including bortezomib and an immunomodulatory… (More)
DOI: 10.1007/s11523-015-0413-6

Topics

2 Figures and Tables

Slides referencing similar topics